Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China (PRNewswire) - Dec 3, 2023 - "Everest Medicines...announced that China National Medical Products Administration (NMPA) has accepted its investigational new drug (IND) application for zetomipzomib in China. Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor currently being evaluated for a range of immune-mediated disorders, including lupus nephritis (LN). Everest plans to join its partner, Kezar Life Sciences, in PALIZADE, a global, placebo-controlled Phase 2b clinical trial evaluating the efficacy and safety of two dose-levels of zetomipzomib in patients with active LN."
Trial status • Lupus Nephritis
|